World's Best Scientists 2026 revealed!
Edward C. Keystone

Edward C. Keystone

D-Index & Metrics

Medicine

D-Index
99
Citations
53894
World Ranking
8425
National Ranking
326

Overview

Edward C. Keystone is affiliated with the University of Toronto in Canada and specializes in medical research. Their work focuses prominently on rheumatology, with extensive contributions in related fields such as hematology, genetics, immunology, and pathology and forensic medicine.

Keystone's research spans a variety of topics, including:

  • Rheumatoid Arthritis Research and Therapies
  • Biosimilars and Bioanalytical Methods
  • Autoimmune and Inflammatory Disorders Research
  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Pharmaceutical Studies and Practices
  • Systemic Lupus Erythematosus Research

They have published extensively in several scientific journals. The most frequent publication venues include:

  • Annals of the Rheumatic Diseases
  • Lara D. Veeken
  • ACR Open Rheumatology
  • RMD Open
  • Arthritis & Rheumatology

Notable recent papers authored or co-authored by Keystone include:

  • Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis, 2022, Nature Genetics
  • Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib, 2020, RMD Open
  • Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study, 2021, Arthritis Research & Therapy
  • Primary and secondary non-response: in need of operational definitions in observational studies, 2021, Annals of the Rheumatic Diseases
  • Improvements in Fatigue Lag Behind Disease Remission in Early Rheumatoid Arthritis: Results From the Canadian Early Arthritis Cohort, 2020, Arthritis & Rheumatology

They collaborate frequently with other researchers in their field. Primary co-authors include:

  • Janet Pope
  • Louis Bessette
  • Glen Hazlewood
  • Susan J. Bartlett
  • Gilles Boire

Best Publications

  • Treating rheumatoid arthritis to target: recommendations of an international task force

    Josef S. Smolen;Daniel Aletaha;Johannes W J W Bijlsma;Ferdinand C Breedveld

  • Genetics of rheumatoid arthritis contributes to biology and drug discovery

    Yukinori Okada;Yukinori Okada;Di Wu;Di Wu;Di Wu;Gosia Trynka;Gosia Trynka;Towfique Raj;Towfique Raj

  • Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy : Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

    Stanley B Cohen;Paul Emery;Maria W Greenwald;Maxime Dougados

  • A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis

    Joan M. Bathon;Richard W. Martin;Roy M. Fleischmann;John R. Tesser

  • Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

    Michael E. Weinblatt;Edward C. Keystone;Daniel E. Furst;Larry W. Moreland

  • Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial

    Larry W. Moreland;Michael H. Schiff;Scott W. Baumgartner;Elizabeth A. Tindall

  • American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

    David T. Felson;David T. Felson;Josef S. Smolen;George Wells;Bi Zhang

  • Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial

    Edward C. Keystone;Arthur F. Kavanaugh;John T. Sharp;Hyman Tannenbaum

  • Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

    E William St Clair;Désirée M F M van der Heijde;Josef S Smolen;Ravinder N Maini

  • Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

    D. E. Furst;E. C. Keystone;J. Braun;F. C. Breedveld

  • Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

    Michael A Gardam;Edward C Keystone;Richard Menzies;Steven Manners

  • Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.

    Mark C. Genovese;Joan M. Bathon;Richard W. Martin;Roy M. Fleischmann

  • IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

    P Emery;E Keystone;H P Tony;A Cantagrel

  • Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).

    Christian E. Antoni;Arthur Kavanaugh;Bruce Kirkham;Zuhre Tutuncu

  • Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

    Edward Keystone;Désireé Van Der Heijde;David Mason;Robert Landewé

  • Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

    Edward C. Keystone;Mark C. Genovese;Lars Klareskog;Elizabeth C. Hsia

  • Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.

    D. Aletaha;R.B. Landewe;T. Karonitsch;J. Bathon

  • Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study

    Désirée van der Heijde;Yoshiya Tanaka;Roy Fleischmann;Edward Keystone

  • The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.

    E. William St.Clair;Carrie L. Wagner;Adedigbo A. Fasanmade;Benjamin Wang

  • Predictors of joint damage in patients with early rheumatoid arthritis treated with high‐dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial

    Josef S. Smolen;Désirée M. F. M. Van Der Heijde;E. William St.Clair;Paul Emery

Frequent Co-Authors

Janet E. Pope
Janet E. Pope University of Western Ontario
Paul Emery
Paul Emery University of Leeds
Mark C. Genovese
Mark C. Genovese Stanford University
Désirée van der Heijde
Désirée van der Heijde Leiden University Medical Center
Daniel E. Furst
Daniel E. Furst University of California, Los Angeles
Michael E. Weinblatt
Michael E. Weinblatt Brigham and Women's Hospital
Bernard Combe
Bernard Combe University of Montpellier
Roy Fleischmann
Roy Fleischmann The University of Texas Southwestern Medical Center
Robert Landewé
Robert Landewé University of Amsterdam
Josef S. Smolen
Josef S. Smolen Medical University of Vienna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always follow a single path. Today, online degrees offer flexible options for those interested in healthcare careers, whether you aim for clinical roles or vital support positions. One fast-track option for nurses is the 1 year dnp program online, which can significantly accelerate your journey to a leadership role in nursing practice.

For those more interested in pharmacy, consider advancing your credentials through an online pharmd program. This pathway prepares you for a wider range of professional opportunities in pharmaceutical care and research.

Students who want to work in healthcare management or information systems can choose rhit programs online. These programs are ideal for understanding health records, privacy laws, and electronic data systems.

Lastly, medical billing and coding remains a popular entry point into healthcare. Understanding the medical coding certification cost helps you budget for quick training that can lead to in-demand remote job opportunities.

Best Scientists Citing Edward C. Keystone

Trending Scientists